Warfarin Sensitivity Genotyping
VKORC1 Promoter Polymorphism6
August 2008
The VKORC1 promoter polymorphism has different frequencies in different populations. In Asian populations, the A promoter allele predominates, and this means that in Asia, the predominate deficiency in warfarin anticoagulation is going to be due to the VKORC1 promoter polymorphism. The *2 and *3 alleles in CYP2C9 are not found that frequently in Asia. On the other hand in Northern European White Populations the G promoter allele predominates and so they may actually require a slightly higher level of anticoagulation due to having a greater amount of protein made.
The warfarin dosing based on genotyping in one study in which they looked at the A and G alleles in the promoter, they found that 83% were able to reach a stable INR within 2 weeks, only 10% had an INR greater than 4 and there were no significant bleeding events in the study, 62% of the dosing variability was explained by the parameters they used and 69% of the participants had actual dose of warfarin match the prediction from the algorithm.
VKORC1 Promoter Polymorphism6 |
Jump to section:
- Introduction
- Warfarin
- Warfarin Anticoagulation
- Warfarin
- Warfarin Monitoring
- Therapeutic Graph
- INR Variability in a 74 Year-old Male
- Warfarin and Bleeding Events
- Warfarin Metabolism
- Polymorphisms and Warfarin Sensitivity
- Polymorphisms and Warfarin Sensitivity
- Summary of Polymorphisms and Warfarin Pharmacokinetics5
- CYP2C9 Association Study
- PGx-Guided Warfarin Dosing7
- Warfarin Pharmacodynamics
- Polymorphisms and Warfarin Sensitivity
- VKORC1 Promoter Polymorphism6
- CYP2C9 and VKORC1 Interaction8
- Genotype-guided Warfarin Dosing9
- Genotype-guided Dosing
- Summary
- Orthopedic Algorithm10
- Significant Warfarin Drug Interactions
- Differential Effect of Drugs
- Patient Case: Rapidly Increasing INR
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document